Home›Trial›NCT06363760
NCT06363760ENROLLING BY INVITATION

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Study Summary

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

Conditions
Sickle Cell DiseaseTransfusion-dependent Beta-ThalassemiaHemoglobinopathies
Interventions / Drugs
Safety and efficacy assessments
View on ClinicalTrials.gov ↗
Sponsor
EDIT
Editas Medicine
Gene Editing
C65/100
Study Details
Enrollment54 participants
Primary Completion—
Lead SponsorEditas Medicine, Inc.
Data Retrieved2026-04-11 04:12:21.598915+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 54 participants
Sponsor Catalyst Profile

Editas Medicine (EDIT) is the sponsoring company for this trial. BiotechSign currently grades this company C (65/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

EDIT Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.